Brian Coleman, Locust Walk’s Managing Director, Global Head of Financing and Sales will be moderating the panel, Drawing Your Financing Roadmap, at BioEquity Europe: Faced with an expanding range of financing options, early stage biotech executives must figure...
Special Report on the U.S. Biopharmaceuticals Industry 2019Selected quotes from the interview with Geoff Meyerson, CEO and Co-Founder of Locust WalkLarge pharma is veering towards bolt-on acquisition deals. How is this impacting the transactions you are involved...
Clear, data-based financial assumptions are essential to driving a successful deal process. In a previous post, The Value of a Commercial Assessment in Supporting a Transaction, I discussed the main ways that a well-done commercial assessment can optimize both the...
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q1 2019 Report: Global Trends in Medtech Transactions applies the latest data to analyze current activities in the life sciences deal...
In this report you can find an overview and analysis of the following across the biopharma market in the US, Europe, and Asia (China and Japan). Key performance indicators for the life science market IPO and private financing activity and performance Deal activity...
